Sara Velázquez-Sánchez-de-Cima1, Gabriela Zamora-Ortiz2, Jesús Hernández-Reyes3, Jocelyn Vargas-Espinosa4, Jessica García-Chavez5, Jaime Rosales-Padrón5, Guillermo J Ruiz-Delgado1, Alejandro Ruiz-Arguelles1, Guillermo J Ruiz-Argüelles6. 1. Centro de Hematología y Medicina Interna de Puebla, Puebla, México Laboratorios Clínicos de Puebla, Díaz Ordaz 808, Puebla, México Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Santiago, Puebla, México. 2. Centro de Hematología y Medicina Interna de Puebla, Puebla, México Laboratorios Clínicos de Puebla, Díaz Ordaz 808, Puebla, México Facultad de Medicina, Universidad de Las Américas Puebla, Cholula, Puebla, México. 3. Centro de Hematología y Medicina Interna de Puebla, Puebla, México Laboratorios Clínicos de Puebla, Díaz Ordaz 808, Puebla, México Facultad de Medicina, Universidad del Valle de México, Villahermosa, México. 4. Centro de Hematología y Medicina Interna de Puebla, Puebla, México Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Santiago, Puebla, México. 5. Centro de Hematología y Medicina Interna de Puebla, Puebla, México Facultad de Medicina, Universidad de Las Américas Puebla, Cholula, Puebla, México. 6. Centro de Hematología y Medicina Interna de Puebla, Puebla, México Laboratorios Clínicos de Puebla, Díaz Ordaz 808, Puebla, México Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Santiago, Puebla, México Facultad de Medicina, Universidad de Las Américas Puebla, Cholula, Puebla, México gruiz1@clinicaruiz.com.
Abstract
INTRODUCTION: The sticky platelet syndrome (SPS) is a common cause of thrombosis. There are no prospective studies concerning treatment. OBJECTIVE: To analyze changes in platelet hyperaggregability of patients with SPS who were given antiplatelet drugs and to assess its association with rethrombosis. METHODS: A total of 55 patients with a history of thrombosis and SPS phenotype were prospectively studied before and after treatment with aspirin and/or clopidogrel. RESULTS: Patients were followed for 1 to 129 months, median 13. Of 55 patients, 40 received aspirin, 13 received aspirin + clopidogrel, and 2 received only clopidogrel. The platelet aggregation response to adenosine diphosphate and epinephrine significantly diminished after treatment, and only 2 patients developed rethrombosis 52 and 129 months after starting therapy, with the freedom from rethrombosis rate of the patients being 96.4% at 129 months. CONCLUSION: Using antiplatelet drugs, the platelet hyperreactivity of patients with the SPS phenotype was reverted; and this translated into a substantial decrease in the rethrombosis rate.
INTRODUCTION: The sticky platelet syndrome (SPS) is a common cause of thrombosis. There are no prospective studies concerning treatment. OBJECTIVE: To analyze changes in platelet hyperaggregability of patients with SPS who were given antiplatelet drugs and to assess its association with rethrombosis. METHODS: A total of 55 patients with a history of thrombosis and SPS phenotype were prospectively studied before and after treatment with aspirin and/or clopidogrel. RESULTS:Patients were followed for 1 to 129 months, median 13. Of 55 patients, 40 received aspirin, 13 received aspirin + clopidogrel, and 2 received only clopidogrel. The platelet aggregation response to adenosine diphosphate and epinephrine significantly diminished after treatment, and only 2 patients developed rethrombosis 52 and 129 months after starting therapy, with the freedom from rethrombosis rate of the patients being 96.4% at 129 months. CONCLUSION: Using antiplatelet drugs, the platelet hyperreactivity of patients with the SPS phenotype was reverted; and this translated into a substantial decrease in the rethrombosis rate.
Authors: Guillermo J Ruiz-Delgado; Yahveth Cantero-Fortiz; Mariana A Mendez-Huerta; Mónica Leon-Gonzalez; Ana K Nuñez-Cortes; Andrés A Leon-Peña; Juan Carlos Olivares-Gazca; Guillermo J Ruiz-Argüelles Journal: Turk J Haematol Date: 2017-02-09 Impact factor: 1.831
Authors: Eray Yagmur; Eva Bast; Anja Susanne Mühlfeld; Alexander Koch; Ralf Weiskirchen; Frank Tacke; Joseph Neulen Journal: J Clin Med Date: 2019-08-28 Impact factor: 4.241